Plasmon-Enhanced ZnO/Ag Nanoparticles Show Synergistic Antibacterial and Anticancer Activities

Strategic Insights -

Researchers have made significant strides in developing nanotechnology-based solutions for biomedical applications. A recent study, published in the journal Plasmonics, highlights the potential of zinc oxide (ZnO) and silver (Ag) nanoparticles as antimicrobial and anticancer agents. The study's findings suggest that the synergistic action of ZnO and Ag nanoparticles could enhance the effectiveness of these agents in combating various bacterial strains and cancer cells.

Key Takeaways:

  • The researchers synthesized ZnO and ZnO/Ag nanoparticles using a green synthesis approach, which is a more environmentally friendly method compared to traditional chemical synthesis.
  • The structural, morphological, and physicochemical properties of the nanoparticles were characterized using X-ray diffraction (XRD), Fourier-transform infrared spectroscopy (FT-IR), transmission electron microscopy (TEM), and dynamic light scattering (DLS).
  • The antibacterial activity of the nanoparticles was assessed against six bacterial strains, including Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Streptococcus mutans, Staphylococcus aureus, and Enterococcus faecalis.
  • ZnO/Ag nanoparticles exhibited superior antibacterial efficacy, particularly against Gram-negative strains, due to the synergistic action of ZnO-mediated oxidative stress and Ag+-induced membrane disruption.
  • The plasmonic properties of Ag further contributed to the antibacterial effect by enhancing reactive oxygen species (ROS) generation under light exposure.
  • The researchers also conducted an MTT assay to evaluate the cytotoxic effect of the nanoparticles on A-549 lung carcinoma cells, which revealed a dose-dependent cytotoxic effect.
  • The enhanced anticancer activity was attributed to increased mitochondrial dysfunction, ROS generation, and apoptosis induction, further amplified by plasmonic interactions.
  • The study underscores the potential of ZnO/Ag nanomaterials as promising candidates for biomedical applications, particularly in antimicrobial and anticancer therapies.

Statistics:

  • The average particle sizes of ZnO and ZnO/Ag nanoparticles were 35 +/- 10 nm and 55 +/- 10 nm, respectively.
  • ZnO/Ag nanoparticles exhibited superior antibacterial efficacy, with a 90% reduction in bacterial growth against Klebsiella pneumoniae and Pseudomonas aeruginosa.
  • The MTT assay revealed a dose-dependent cytotoxic effect of ZnO/Ag nanoparticles on A-549 lung carcinoma cells, with a 50% reduction in cell viability at 100 μg/mL concentration.
  • The enhanced anticancer activity of ZnO/Ag nanoparticles was attributed to increased mitochondrial dysfunction, ROS generation, and apoptosis induction, which were further amplified by plasmonic interactions.

Sources:

  • NewsRx. New Findings from College of Pharmacy in the Area of Nanoparticles Reported (Plasmon-enhanced Zno/ag Nanoparticles With Synergistic Antibacterial and Anticancer Activities). Cancer Weekly. July 8, 2025; p 1201.
  • Ali Abbasi et al. Plasmon-enhanced Zno/ag Nanoparticles With Synergistic Antibacterial and Anticancer Activities. Plasmonics, 2025.